VanEck Associates
SAGE

VanEck Associates’s Sage Therapeutics SAGE Stock Holding History

VanEck Associates’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,203
Closed -$53K – 1404
2021
Q3 		$53K Buy
1,203
+448
+59% +$20.5K ﹤0.01% 1233
2021
Q2 		$43K Buy
+755
New +$53.4K ﹤0.01% 1216

Other funds holding SAGE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

VanEck Associates's SAGE Position: Q4 2021 in Review

VanEck Associates sold out of Sage Therapeutics (SAGE) in Q4 2021, closing a stake of 1,203 shares — an estimated $53K sold.

VanEck Associates first reported a position in SAGE in Q2 2021 and held it in 2 quarters. The position peaked at $53K in Q3 2021. 216 funds tracked by Wall St. Rank hold SAGE as of Q4 2021.

  • VanEck Associates reported no remaining Sage Therapeutics position as of Q4 2021 after selling out during the quarter.
  • VanEck Associates sold 1,203 Sage Therapeutics shares in Q4 2021, an estimated $53K.
  • VanEck Associates first reported a position in Sage Therapeutics in Q2 2021 and held it in 2 quarters.
  • VanEck Associates's Sage Therapeutics position peaked at $53K in Q3 2021.
  • 216 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2021.

Based on VanEck Associates's 13F filing for Q4 2021, filed 26 Jan 2022.